193 related articles for article (PubMed ID: 37698749)
1. Heterologous expression of fungal L-asparaginase: a systematic review.
Rodrigues Andrade KC; Cordeiro de Abreu JA; Guimarães MB; Abrunhosa LS; Leôncio Rodrigues AL; Fonseca-Bazzo YM; Silveira D; Souza PM; Magalhães PO
Future Microbiol; 2024 Jan; 19():157-171. PubMed ID: 37882841
[TBL] [Abstract][Full Text] [Related]
2. Cathepsin B Is Not an Intrinsic Factor Related to Asparaginase Resistance of the Acute Lymphoblastic Leukemia REH Cell Line.
Costa IM; Effer B; Costa-Silva TA; Chen C; Ciccone MF; Pessoa A; Dos Santos CO; Monteiro G
Int J Mol Sci; 2023 Jul; 24(13):. PubMed ID: 37446393
[TBL] [Abstract][Full Text] [Related]
3. A new extracellular glutaminase and urease-free L-asparaginase from Meyerozyma guilliermondii.
Ratuchne A; Izidoro SC; Beitel SM; Lacerda LT; Knob A
Braz J Microbiol; 2023 Jun; 54(2):715-723. PubMed ID: 36917331
[TBL] [Abstract][Full Text] [Related]
4. Biochemical characterization of glutaminase-free L-asparaginases from Himalayan Pseudomonas and Rahnella spp. for acrylamide mitigation.
Patial V; Kumar S; Joshi R; Singh D
Int J Biol Macromol; 2024 Feb; 257(Pt 2):128576. PubMed ID: 38048933
[TBL] [Abstract][Full Text] [Related]
5. Superior operational stability of immobilized L-asparaginase over surface-modified carbon nanotubes.
Almeida MR; Cristóvão RO; Barros MA; Nunes JCF; Boaventura RAR; Loureiro JM; Faria JL; Neves MC; Freire MG; Santos-Ebinuma VC; Tavares APM; Silva CG
Sci Rep; 2021 Nov; 11(1):21529. PubMed ID: 34728685
[TBL] [Abstract][Full Text] [Related]
6. Identification and structural analysis of an L-asparaginase enzyme from guinea pig with putative tumor cell killing properties.
Schalk AM; Nguyen HA; Rigouin C; Lavie A
J Biol Chem; 2014 Nov; 289(48):33175-86. PubMed ID: 25320094
[TBL] [Abstract][Full Text] [Related]
7. A Structural In Silico Analysis of the Immunogenicity of L-Asparaginase from
Andrade KCR; Homem-de-Mello M; Motta JA; Borges MG; de Abreu JAC; de Souza PM; Pessoa A; Pappas GJ; de Oliveira Magalhães P
Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38732010
[TBL] [Abstract][Full Text] [Related]
8. First-line treatment of acute lymphoblastic leukemia with pegasparaginase.
Masetti R; Pession A
Biologics; 2009; 3():359-68. PubMed ID: 19707421
[TBL] [Abstract][Full Text] [Related]
9. Desirable L-asparaginases for treating cancer and current research trends.
Tsegaye K; Tsehai BA; Getie B
Front Microbiol; 2024; 15():1269282. PubMed ID: 38591038
[TBL] [Abstract][Full Text] [Related]
10. Metagenomic discovery and functional validation of L-asparaginases with anti-leukemic effect from the Caspian Sea.
Sobat M; Asad S; Kabiri M; Mehrshad M
iScience; 2021 Jan; 24(1):101973. PubMed ID: 33458619
[TBL] [Abstract][Full Text] [Related]
11. The combination of calreticulin-targeting L-ASNase and anti-PD-L1 antibody modulates the tumor immune microenvironment to synergistically enhance the antitumor efficacy of radiotherapy.
Zhang Y; Akhil V; Seo HS; Park HR; Kim SH; You SH; Liu Z; Kim SY; Sultonova RD; Min JJ; Hong Y
Theranostics; 2024; 14(3):1195-1211. PubMed ID: 38323311
[TBL] [Abstract][Full Text] [Related]
12. Engineering and Expression Strategies for Optimization of L-Asparaginase Development and Production.
Shishparenok AN; Gladilina YA; Zhdanov DD
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894901
[TBL] [Abstract][Full Text] [Related]
13. Development of asparaginase Erwinia chrysanthemi for the treatment of acute lymphoblastic leukemia.
Salzer WL; Asselin BL; Plourde PV; Corn T; Hunger SP
Ann N Y Acad Sci; 2014 Nov; 1329():81-92. PubMed ID: 25098829
[TBL] [Abstract][Full Text] [Related]
14. L-asparaginase production review: bioprocess design and biochemical characteristics.
Castro D; Marques ASC; Almeida MR; de Paiva GB; Bento HBS; Pedrolli DB; Freire MG; Tavares APM; Santos-Ebinuma VC
Appl Microbiol Biotechnol; 2021 Jun; 105(11):4515-4534. PubMed ID: 34059941
[TBL] [Abstract][Full Text] [Related]
15. In Silico Design of a Chimeric Humanized L-asparaginase.
Pedroso A; Herrera Belén L; Beltrán JF; Castillo RL; Pessoa A; Pedroso E; Farías JG
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108713
[TBL] [Abstract][Full Text] [Related]
16. Comparison of intramuscular therapy with Erwinia asparaginase and asparaginase Medac: pharmacokinetics, pharmacodynamics, formation of antibodies and influence on the coagulation system.
Albertsen BK; Schrøder H; Ingerslev J; Jakobsen P; Avramis VI; Müller HJ; Carlsen NT; Schmiegelow K
Br J Haematol; 2001 Dec; 115(4):983-90. PubMed ID: 11843837
[TBL] [Abstract][Full Text] [Related]
17. Pharmacology, immunogenicity, and efficacy of a novel pegylated recombinant Erwinia chrysanthemi-derived L-asparaginase.
Chien WW; Allas S; Rachinel N; Sahakian P; Julien M; Le Beux C; Lacroix CE; Abribat T; Salles G
Invest New Drugs; 2014 Oct; 32(5):795-805. PubMed ID: 24829072
[TBL] [Abstract][Full Text] [Related]
18. Enzyme Engineering Strategies for the Bioenhancement of L-Asparaginase Used as a Biopharmaceutical.
Miranda J; Lefin N; Beltran JF; Belén LH; Tsipa A; Farias JG; Zamorano M
BioDrugs; 2023 Nov; 37(6):793-811. PubMed ID: 37698749
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
